Aloesin |
Catalog No.GC38398
One-Click Copy Product Info
|
Aloesin is a potent and selective inhibitor of tyrosinase with IC50 value of 31.5μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 30861-27-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Aloesin is a potent and selective inhibitor of tyrosinase with IC50 value of 31.5μM [1]. Aloesin has direct inhibitory effects on melanogenesis and showed dose-dependent reductions in tyrosinase activity[2]. Aloesin has been widely used to inhibit excessive pigmentation caused by ultraviolet radiation[3].
In vitro, Aloesin treatment for 48 hours significantly inhibited the proliferation of SKOV3 cells, with an IC50 value of 5μM[4]. Without the presence of Wnt3a ligand, treatment with 20μM Aloesin for 12 hours can increase the protein level of active β-catenin in NIH/3T3 cells, and promote the expression of Wnt cascade genes[5]. Treatment with 20μM Aloesin for 24 hours significantly increased the levels of cyclin E, CDK2 and CDC25A in SK-HEP-1 cells[6].
In vivo, Aloesin treatment via oral administration at a dose of 40mg/kg/day for 7 consecutive days effectively reduced psoriasis area severity index (PASI) scores without any significant changes in the body weight of mice and ameliorated psoriatic lesions [7]. Administer Aloesin (200mg/kg) orally twice a week for 12 weeks significantly reduced obesity-related oxidative stress and hepatic steatosis in rats fed with a high-fat diet (HFD)[8].
References:
[1] Mikayoulou M, Mayr F, Temml V, et al. Anti-tyrosinase activity of South African Aloe species and isolated compounds plicataloside and aloesin[J]. Fitoterapia, 2021, 150: 104828.
[2] Wang Z, Li X, Yang Z, et al. Effects of aloesin on melanogenesis in pigmented skin equivalents[J]. International journal of cosmetic science, 2008, 30(2): 121-130.
[3] Choi S, Park Y I, Lee S K, et al. Aloesin inhibits hyperpigmentation induced by UV radiation[J]. Clinical and experimental dermatology, 2002, 27(6): 513-515.
[4] Zhang L, Lv R, Qu X, et al. Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3 cells through the inhibition of the MAPK signaling pathway[J]. Analytical Cellular Pathology, 2017, 2017(1): 8158254.
[5] Peng C, Zhang W J, Dai C, et al. Study of the aqueous extract of Aloe vera and its two active components on the Wnt/β-catenin and Notch signaling pathways in colorectal cancer cells[J]. Journal of ethnopharmacology, 2019, 243: 112092.
[6] Lee K Y, Park J H, Chung M H, et al. Aloesin up‐regulates cyclin E/CDK2 kinase activity via inducing the protein levels of cyclin E, CDK2, and CDC25A in SK‐HEP‐1 cells[J]. IUBMB Life, 1997, 41(2): 285-292.
[7] Alsahli T G, Alharbi K S, Alenezi S K, et al. Aloesin alleviates imiquimod-induced psoriasis in dermal layers through inhibition of interleukins and NF-κB signaling pathways[J]. Scientific Reports, 2025.
[8] Alamri S M, Al-Harbi L N, Alshammari G M, et al. Aloesin activates Nrf2 signaling to attenuate obesity-associated oxidative stress and hepatic steatosis in high-fat diet-fed rats[J]. Scientific Reports, 2025, 15(1): 34888.
| Cell experiment [1]: | |
Cell lines | SKOV3 cells |
Preparation Method | SKOV3 cells were cultured in a medium supplemented with 10% fetal bovine serum (FBS) and 100U/ml penicillin/streptomycin. The cells were incubated in a humidified environment at 37°C with 5% CO2. SKOV3 cells were seeded at a density of 5×103 cells per well in a 96-well plate and cultured overnight. Then, the cells were treated with different concentrations (0, 2.5, 5, 10, 20, and 40μM) of Aloesin for 48 hours, and the cell viability after aloin treatment was analyzed. |
Reaction Conditions | 0, 2.5, 5, 10, 20, and 40μM; 48h |
Applications | Aloesin treatment inhibited the growth of SKOV3 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Wistar albino rats |
Preparation Method | Wistar albino rats (120±15g) were placed in standard laboratory cages lined with suitable wood chips and maintained in a controlled environment with a temperature of (20-22°C) and humidity of (40-60%). A 12-hour light/12-hour dark daily cycle was maintained throughout the entire study period. The rats had free access to food and water. After one week of adapting to the environment, 24 adult rats were randomly divided into 3 groups (n=8 in each group): (1) Control group (standard diet+solvent); (2) Control group+Aloesin (200mg/kg); (3) HFD+Aloesin (200mg/kg), with the Aloesin administered orally twice a week for 12 weeks. Liver tissues of the rats were collected for analysis. |
Dosage form | 200mg/kg; twice a week for 12 weeks; p.o. |
Applications | Aloesin reduced liver damage and mitigated the increase in liver enzymes in HFD-fed rats. |
References: | |
| Cas No. | 30861-27-9 | SDF | |
| Canonical SMILES | OC1=CC(C)=C(C(C=C(CC(C)=O)O2)=O)C2=C1[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO | ||
| Formula | C19H22O9 | M.Wt | 394.37 |
| Solubility | DMSO: 270 mg/mL (684.64 mM) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5357 mL | 12.6784 mL | 25.3569 mL |
| 5 mM | 507.1 μL | 2.5357 mL | 5.0714 mL |
| 10 mM | 253.6 μL | 1.2678 mL | 2.5357 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)